EGFR and non-small cell lung carcinoma: In addition, another unique insertion D770delinsGY also sensitizes NSCLC cell lines and patients to 2nd- or 3rd-gen EGFR TKIs (Jänne et al., 2011; Kosaka et al., 2017; Yang et al., 2020; Yang J et al., 2021).